Driving growth in a family-owned pharma company requires a balance of progress and preservation, writes Merz Therapeutics CEO ...

Fear of change is a key limiting factor that is slowing the adoption and value of AI across life sciences. It doesn't have to ...

Sometimes the key to making a breakthrough in research, in any field, is to look at the problem differently than anybody has ...

Tolga Tanguler, EVP and Chief Commercial Officer at Alnylam Pharmaceuticals, discusses the global opportunity for the commercialization of RNAi therapies with host Ben Comer. Catch the full episode ...

In this chapter of Business of Biotech episode 252, Alnylam Chief Commercial Officer Tolga Tanguler shares on the company's strategy to pivot its RNAi therapeutic applications from rare to large ...

<p>On this week&#39;s episode of the Business of Biotech, Barry Quart, CEO of Connect Biopharma, weighs in on the current state of engagement between drug developers and the FDA, and how that key ...

<p>On this week&#39;s episode of the Business of Biotech, Jennifer Hawks Bland, CEO of NewYorkBIO, shares insights on New York State&#39;s life sciences ecosystem while reflecting on her journey from ...

Cuts to federal research funding at universities and research organizations are pushing academic scientists into life sciences entrepreneurship. Experts at Sidley offer tips for the transition.

BIO was as busy as ever in Boston this year. With more to come soon, here are a few initial thoughts on three events I attended.

Smart money will find good ideas, and if you follow the money in biotech these days, that means looking to China. From January to mid-May 2025, Chinese biotechnology companies had announced licensing ...

By Stephen Beckman Stephen Beckman A revolution is coming in the U.S. generics marketplace, one that players in the space ignore at their peril. This revolution has the potential to transform savvy ...

The biopharma industry is rapidly evolving. As such, biopharma companies are facing a variety of operational challenges stemming from a high volume of siloed data coupled with regulatory scrutiny that ...